Pain points
Foundayo Safety Questions Cloud GLP-1 Momentum
The FDA's April 14 request for additional cardiovascular and hepatic data on Eli Lilly's oral GLP-1 raises patient confidence concerns even as prices fall across the category.
Primary sources · 1